Trial Profile
Injection technique and individual characteristics associated with local reactogenicity to quadrivalent human papillomavirus vaccine in young women
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- Acronyms FAR Trial
- 06 Sep 2012 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
- 18 Jul 2011 New trial record